Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
Several...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adenosine Signaling in Primary and Metastatic Brain Tumors: Immune Suppression, Tumor Progression, and Therapeutic Opportunities.

Molecular neurobiology·2026
Same author

Targeting purinergic signaling and MTAP-associated metabolism in cancer: A functional immunometabolic convergence framework.

Biochemical pharmacology·2026
Same author

Genetic alterations in SUPT6H are associated with neurodevelopmental disorders.

Biochimica et biophysica acta. Molecular basis of disease·2026
Same author

AES-NINDS Epilepsy Benchmarks Area IV: Comorbidities of Epilepsy - Where Are We and Where Will We Go?

Epilepsy currents·2026
Same author

Commonalities in gene expression and methylation changes across two rat models of acquired epilepsy.

Scientific reports·2026
Same author

The Concise Guide to PHARMACOLOGY 2025/26: Enzymes.

British journal of pharmacology·2025

Related Experiment Video

Updated: Jun 10, 2026

Determining the Serum Stability of Human Adenosine Deaminase 1 Enzyme
04:17

Determining the Serum Stability of Human Adenosine Deaminase 1 Enzyme

Published on: September 27, 2024

Adenosine dysfunction and adenosine kinase in epileptogenesis.

Detlev Boison1

  • 1RS Dow Neurobiology Laboratories, Legacy Research, Portland, OR 97232, USA.

The Open Neuroscience Journal
|August 24, 2010
PubMed
Summary

Epilepsy may stem from astrocyte dysfunction, not just neurons. Inhibiting adenosine kinase (ADK) and boosting adenosine levels shows promise for treating drug-resistant epilepsy.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Pharmacology

Background:

  • Epilepsy traditionally viewed as a neuronal disorder, with treatments targeting neurons.
  • Approximately 30% of epilepsy patients are refractory to current neurocentric pharmacotherapy.
  • Emerging research implicates astrocyte dysfunction in epilepsy pathogenesis.

Purpose of the Study:

  • To review the role of astrocyte-based adenosine kinase (ADK) in epilepsy.
  • To explore ADK as a novel therapeutic target for refractory epilepsy.
  • To discuss adenosine augmentation therapies (AATs) for epilepsy.

Main Methods:

  • Focus on astrocyte-based enzyme adenosine kinase (ADK) as a key regulator of synaptic adenosine.
  • Review of evidence from transgenic animal models showing ADK overexpression triggers seizures.

More Related Videos

Implantation of Electroencephalogram and Electrocardiogram Telemetry Devices in Neonatal Rabbit Kits
06:46

Implantation of Electroencephalogram and Electrocardiogram Telemetry Devices in Neonatal Rabbit Kits

Published on: February 28, 2025

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
09:07

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Published on: August 15, 2017

Related Experiment Videos

Last Updated: Jun 10, 2026

Determining the Serum Stability of Human Adenosine Deaminase 1 Enzyme
04:17

Determining the Serum Stability of Human Adenosine Deaminase 1 Enzyme

Published on: September 27, 2024

Implantation of Electroencephalogram and Electrocardiogram Telemetry Devices in Neonatal Rabbit Kits
06:46

Implantation of Electroencephalogram and Electrocardiogram Telemetry Devices in Neonatal Rabbit Kits

Published on: February 28, 2025

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
09:07

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Published on: August 15, 2017

  • Examination of pharmacological inhibition of ADK and its efficacy in seizure suppression.

    • Main Results:

    • Astrogliosis in epileptic brains leads to ADK overexpression and adenosine deficiency.
    • ADK overexpression is sufficient to induce seizures in animal models.
    • Pharmacological ADK inhibition effectively suppresses seizures resistant to conventional drugs.

    Conclusions:

    • Astrocyte dysfunction, specifically involving ADK, is a critical factor in epilepsy.
    • Targeting ADK offers a promising strategy for novel anti-epileptic therapies.
    • Adenosine augmentation therapies (AATs) represent a potential treatment for refractory epilepsy by restoring adenosinergic signaling.